 |
|
 |
|
|
 |
|||
       |
|||
|
|||
 |
|||
|
|||
Segment Results - 4 th Quarter Fiscal Year 2007
- TECHNE Corporation and Subsidiaries
- Hematology Division
- Biotechnology Division
- R&D Systems Europe (in £'s)
- R&D Systems Europe (in $'s)
- Corporate and Other
| Fiscal 2007 | Increase(Decrease) From Fiscal 2006 | ||||||||||
| First Quarter | Second Quarter | Third Quarter | Fourth Quarter | YTD | Percent Of Sales | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | YTD | |
Sales |
52,351 |
52,509 |
60,197 |
58,425 |
223,482 |
100% |
4,642 |
4,480 |
5,384 |
6,359 |
20,865 |
Cost of sales |
11,237 |
10,714 |
12,019 |
12,697 |
46,667 |
21% |
141 |
19 |
(86) |
875 |
949 |
Gross margin |
41,114 |
41,795 |
48,178 |
45,728 |
176,815 |
79% |
4,501 |
4,461 |
5,470 |
5,484 |
19,916 |
Gross margin percentage |
78.5% |
79.6% |
80.0% |
78.3% |
79.1% |
||||||
SG&A expense |
7,067 |
8,830 |
7,229 |
7,839 |
30,965 |
14% |
613 |
850 |
328 |
1,570 |
3,361 |
R&D expense |
4,855 |
5,044 |
5,169 |
5,014 |
20,082 |
9% |
138 |
470 |
408 |
241 |
1,257 |
Amortization expense |
403 |
404 |
403 |
404 |
1,614 |
1% |
(89) |
(88) |
(89) |
(87) |
(353) |
Interest expense |
268 |
815 |
0 |
0 |
1,083 |
0% |
45 |
577 |
(245) |
(258) |
119 |
Interest income |
(1,676) |
(1,956) |
(2,237) |
(2,565) |
(8,434) |
(4%) |
(702) |
(826) |
(1,155) |
(1,043) |
(3,726) |
Other non-operating ex., net |
485 |
428 |
767 |
894 |
2,574 |
1% |
274 |
147 |
538 |
531 |
1,490 |
11,402 |
13,565 |
11,331 |
11,586 |
47,884 |
21% |
279 |
1,130 |
(215) |
954 |
2,148 |
|
Earnings before income taxes |
29,712 |
28,230 |
36,847 |
34,142 |
128,931 |
58% |
4,222 |
3,331 |
5,685 |
4,530 |
17,768 |
Income taxes |
10,081 |
9,567 |
12,954 |
11,218 |
43,820 |
20% |
1,592 |
1,182 |
2,139 |
1,095 |
6,008 |
|
19,631 |
18,663 |
23,893 |
22,924 |
85,111 |
38% |
2,630 |
2,149 |
3,546 |
3,435 |
11,760 |
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
.50 |
.47 |
.60 |
.58 |
2.15 |
||||||
Weighted average diluted shares outstanding |
39,469 |
39,511 |
39,543 |
39,555 |
39,513 |
||||||
Back to Top
| Fiscal 2007 | Increase(Decrease) From Fiscal 2006 | ||||||||||
| First Quarter | Second Quarter | Third Quarter | Fourth Quarter | YTD | Percent Of Sales | First Quarter | Second Quarter | Third Qurter | Fourth Quarter | YTD | |
Sales |
3,502 |
3,826 |
3,664 |
4,110 |
15,102 |
100% |
(32) |
45 |
(36) |
(114) |
(137) |
Cost of sales |
2,098 |
2,147 |
2,085 |
2,258 |
8,588 |
57% |
(7) |
13 |
(15) |
(1) |
(10) |
Gross margin |
1,404 |
1,679 |
1,579 |
1,852 |
6,514 |
43% |
(25) |
32 |
(21) |
(113) |
(127) |
Gross margin percentage |
40.1% |
43.9% |
43.1% |
45.1% |
43.1% |
||||||
SG&A expense |
398 |
439 |
431 |
422 |
1,690 |
11% |
14 |
15 |
(10) |
46 |
65 |
R&D expense |
180 |
190 |
198 |
181 |
749 |
5% |
(5) |
20 |
30 |
(7) |
38 |
Interest, net |
(81) |
(95) |
(111) |
(136) |
(423) |
(3%) |
(44) |
(45) |
(71) |
(62) |
(222) |
497 |
534 |
518 |
467 |
2,016 |
13% |
(35) |
(10) |
(51) |
(23) |
(119) |
|
Pretax result |
907 |
1,145 |
1,061 |
1,385 |
4,498 |
30% |
10 |
42 |
30 |
(90) |
(8) |
Back to Top
| Fiscal 2007 | Increase(Decrease) From Fiscal 2006 | ||||||||||
| First Quarter | Second Quarter | Third Quarter | Fourth Quarter | YTD | Percent Of Sales | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | YTD | |
Sales |
41,621 |
40,073 |
46,202 |
44,788 |
172,684 |
100% |
4,022 |
2,376 |
3,189 |
4,712 |
14,299 |
Intersegment sales |
(5,699) |
(6,647) |
(7,072) |
(6,652) |
(26,070) |
|
(400) |
(92) |
(676) |
(941) |
(2,109) |
|
35,922 |
33,426 |
39,130 |
38,136 |
146,614 |
|
3,622 |
2,284 |
2,513 |
3,771 |
12,190 |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
8,482 |
7,683 |
9,041 |
9,577 |
34,783 |
20% |
12 |
(464) |
(84) |
980 |
444 |
Intersegment sales |
(5,524) |
(6,435) |
(7,147) |
(6,679) |
(25,785) |
|
(201) |
(295) |
(669) |
(922) |
(2,087) |
|
2,958 |
1,248 |
1,894 |
2,898 |
8,998 |
|
(189) |
(759) |
(753) |
58 |
(1,643) |
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin |
32,964 |
32,178 |
37,236 |
35,238 |
137,616 |
80% |
3,811 |
3,043 |
3,266 |
3,713 |
13,833 |
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin percentage |
79.6% |
80.8% |
80.4% |
78.6% |
79.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SG&A expense |
4,013 |
4,664 |
4,166 |
4,617 |
17,460 |
10% |
374 |
470 |
(33) |
1,207 |
2,018 |
R&D expense |
4,675 |
4,854 |
4,971 |
4,833 |
19,333 |
11% |
143 |
450 |
378 |
248 |
1,219 |
Amortization expense |
403 |
404 |
403 |
404 |
1,614 |
2% |
(89) |
(88) |
(89) |
(87) |
(353) |
Interest, net |
(595) |
(722) |
(841) |
(1,031) |
(3,189) |
(2%) |
(327) |
(349) |
(556) |
(530) |
(1,762) |
|
8,496 |
9,200 |
8,699 |
8,823 |
35,218 |
21% |
101 |
483 |
(300) |
838 |
1,122 |
Pretax result |
24,468 |
22,978 |
28,537 |
26,415 |
102,398 |
59% |
3,710 |
2,560 |
3,566 |
2,875 |
12,711 |
(1) Includes R&D Systems' Biotechnology Division, Fortron Bio Science, Inc., and BiosPacific, Inc.
Back to Top
| Fiscal 2007 | Increase(Decrease) From Fiscal 2006 | ||||||||||
| First Quarter | Second Quarter | Third Quarter | Fourth Quarter | YTD | Percent Of Sales | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | YTD | |
Sales |
6,870 |
7,851 |
8,854 |
8,154 |
31,729 |
100% |
180 |
322 |
598 |
876 |
1,976 |
Cost of sales |
3,285 |
3,766 |
4,091 |
3,797 |
14,939 |
47% |
(7) |
1 |
(100) |
167 |
61 |
Gross margin |
3,585 |
4,085 |
4,763 |
4,357 |
16,790 |
53% |
187 |
321 |
698 |
709 |
1,915 |
Gross margin percentage |
52.2% |
52.0% |
53.8% |
53.4% |
52.9% |
||||||
SG&A expense |
1,074 |
1,236 |
1,075 |
1,113 |
4,498 |
14% |
70 |
51 |
5 |
(2) |
124 |
Interest income |
(410) |
(480) |
(542) |
(595) |
(2,027) |
(6%) |
(84) |
(151) |
(200) |
(226) |
(661) |
Exchange loss/(gain) |
78 |
(64) |
22 |
6 |
42 |
-- |
63 |
(90) |
71 |
15 |
59 |
742 |
692 |
555 |
524 |
2,513 |
8% |
49 |
(190) |
(124) |
(213) |
(478) |
|
Pretax result |
2,843 |
3,393 |
4,208 |
3,833 |
14,277 |
45% |
138 |
511 |
822 |
922 |
2,393 |
Back to Top
| Fiscal 2007 | Increase(Decrease) From Fiscal 2006 | ||||||||||
| First Quarter | Second Quarter | Third Quarter | Fourth Quarter | YTD | Percent Of Sales | First Quarter | Second Quarter | Fourth Quarter | Third Quarter | YTD | |
Sales |
12,927 |
15,257 |
17,403 |
16,179 |
61,766 |
100% |
1,052 |
2,151 |
2,907 |
2,702 |
8,812 |
Cost of sales |
6,181 |
7,319 |
8,040 |
7,541 |
29,081 |
47% |
337 |
765 |
682 |
818 |
2,602 |
Gross margin |
6,746 |
7,938 |
9,363 |
8,638 |
32,685 |
53% |
715 |
1,386 |
2,225 |
1,884 |
6,210 |
Gross margin percentage |
52.2% |
52.0% |
53.8% |
53.4% |
52.9% |
||||||
SG&A expense |
2,020 |
2,405 |
2,112 |
2,219 |
8,756 |
14% |
238 |
346 |
233 |
155 |
972 |
Interest income |
(771) |
(933) |
(1,067) |
(1,174) |
(3,945) |
(6%) |
(192) |
(361) |
(467) |
(494) |
(1,514) |
Exchange loss |
147 |
(126) |
42 |
19 |
82 |
-- |
119 |
(172) |
129 |
36 |
112 |
1,396 |
1,346 |
1,087 |
1,064 |
4,893 |
8% |
165 |
(187) |
(105) |
(303) |
(430) |
|
Pretax result |
5,350 |
6,592 |
8,276 |
7,574 |
27,792 |
45% |
550 |
1,573 |
2,330 |
2,187 |
6,640 |
Back to Top
| Fiscal 2007 | Increase(Decrease) From Fiscal 2006 | |||||||||
| First Quarter | Second Quarter | Third Quarter | Fourth Quarter | YTD | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | YTD | |
Interest income |
229 |
206 |
218 |
224 |
877 |
139 |
71 |
61 |
(43) |
228 |
Rental income |
299 |
241 |
55 |
91 |
686 |
(43) |
(96) |
(232) |
(229) |
(600) |
528 |
447 |
273 |
315 |
1,563 |
96 |
(25) |
(171) |
(272) |
(372) |
|
SG&A expense |
636 |
1,322 |
520 |
581 |
3,059 |
(13) |
19 |
138 |
162 |
306 |
Interest expense |
268 |
815 |
0 |
0 |
1,083 |
45 |
577 |
(245) |
(258) |
119 |
Other-Building expenses |
510 |
549 |
519 |
634 |
2,212 |
67 |
59 |
(1) |
105 |
230 |
Other-Hemerus losses |
127 |
123 |
119 |
169 |
538 |
45 |
41 |
36 |
(2) |
120 |
Other-Nephromics losses |
-- |
123 |
142 |
163 |
428 |
-- |
123 |
142 |
163 |
428 |
1,541 |
2,932 |
1,300 |
1,547 |
7,320 |
144 |
819 |
70 |
170 |
1,203 |
|
Pretax result |
(1,013) |
(2,485) |
(1,027) |
(1,232) |
(5,757) |
(48) |
(844) |
(241) |
(442) |
(1,575) |
Back to Top
(2) Unallocated corporate expenses and Techne’s share of losses by Hemerus Medical, LLC and Nephromics, LLC.